Canadian life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) said on Tuesday that it has activated its first clinical site and enrolled the initial patient in the Phase 2a UTOPIA-1 trial.

The study is being conducted at the Centre Hospitalier de l'Université de Montréal (CHUM), which continues to recruit additional participants.

UTOPIA-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer experiencing moderate to severe pain.

The enrolment milestone represents progress in ZYUS Life Sciences' clinical development program and reflects its focus on advancing non-opioid therapeutic options for cancer-related pain.

According to President and CEO Brent Zettl, Trichomylin softgel capsules are intended to address the gap between conventional pain treatments, including opioids and NSAIDs, by providing a differentiated pharmaceutical approach. He emphasised that the trial is expected to generate meaningful clinical data that could improve patient outcomes while creating long-term value for shareholders.